Taken public, the way it works is what money went in the company, what was the appraisal which is public Marshal Stevens put on the assets and what is the same for the possible merger company as announced, and then you sell that valuation to a market maker based on real analytics, period, what happens from their is based on execution and demand of course, so no idea after it opens, the only difference from last valuation is we now have Merck as a partner with Keytruda and anlicense with the Chinese company for prostate where they pay everything!